Discrepancy Between Radiologic and Pathologic Measurements in Pancreatic Neuroendocrine Tumors: A Retrospective Study on 199 Patients Abstract #1165

Introduction: Preoperative radiologic size of pancreatic neuroendocrine tumors (PNET) is a crucial parameter in selection of appropriate treatment especially for incidentally discovered lesions (<20 mm). The current guideline bases the therapeutic recommendations on the pathologic size.
Aim(s): Evaluate the discrepancy between radiologic size (RS) and pathologic size (PS) of PNET
Materials and methods: Patients resected for PNET between January 2004 and November 2014 at our Institution were retrieved from a electronic database and analyzed retrospectively. We excluded functioning and cystic PNET and R2 resections. RS is defined as the mean of the largest diameters measured on CT, EUS and MRI, and PS as the largest diameter of the tumor on the histological report of the surgical specimen
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Surgical treatment
Presenting Author: MD Anna Malpaga
Keywords: size NET

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1902 18F-FDG Positron Emission Tomography/Computed Tomography Positivity in Small Incidentally-Found Pancreatic Neuroendocrine Tumors: Could It Be Considered a Predictor of Malignancy?
Introduction: Surgical management of small (
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Surgical treatment
Presenting Author: Doctor Anna Malpaga
#1174 Long-Term Follow-Up of Resected Small (< 2 Cm) Asymptomatic Sporadic Non-Functioning Pancreatic Neuroendocrine Tumors: Correlation Between Type of Resection, Histopathologic Features, and Outcome
Introduction: The surgical management of small, incidentally found sporadic non-functioning pancreatic neuroendocrine tumors (NF-PNET) is controversial
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Surgical treatment
Presenting Author: MD Anna Malpaga
Keywords: small
#1834 Sporadic Panglandular Non-Functioning pNET: New Entities? A Case Series
Introduction: Sporadic panglandular pancreatic neuroendocrine tumors (PanNETs) have never been described yet.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Clinical cases/reports
Presenting Author: Caterina Costanza Zingaretti
#3075 Telotristat Makes Significant Difference on Symptoms and Serotonin Levels in a Population with Widespread GI-NET and Severe Carcinoid Syndrome
Introduction: In spite of new treatments like PRRT or everolimus there is a clinical need for systemic therapies that complement SSAs (somatostatin analogs) and antidiarrheal agents in the treatment of carcinoid syndrome, a late stage problem in s-i-NET. Telotristat is a promising addition to our therapeutic arsenal.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - others, not specified
Presenting Author: MD PhD Kristina Linder Ekberg
Authors: Linder Ekberg K, ...
#2926 O-Positive Blood Group Is Associated with Prolonged Recurrence-Free Survival Following Pancreatic Neuroendocrine Tumor (PanNET) Curative-Intent Surgical Resection
Introduction: The ABO blood group may influence the development and progression of cancer. In particular, the prognosis of pancreatic adenocarcinoma is better in patients with blood group O. This has not been extensively explored in PanNET.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Dr Louis de Mestier